UBS maintains buy rating for Sanofi with target price of 110 euros

Sanofi has received a "Buy" rating from UBS, with a target price of 110 euros, after reporting its third-quarter results.

Analyst Jo Walton noted that Sanofi's sales exceeded both his and market consensus estimates, driven by strong vaccine sales.

The report, published on October 25, 2024, suggests a positive outlook for Sanofi, indicating strong performance in the pharmaceutical sector.

Investors are optimistic about the company's ability to outperform in a competitive market.

Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings